Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders

Authors: Schiff E.R.1; Dienstag J.L.; Karayalcin S.; Grimm I.S.; Perrillo R.P.; Husa P.; de Man R.A.; Goodman Z.; Condreay L.D.; Crowther L.M.; Woessner M.A.; McPhillips P.J.; Brown N.A.; the International Lamivudine Investigator Group

Source: Journal of Hepatology, Volume 38, Number 6, June 2003 , pp. 818-826(9)

Publisher: Elsevier

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Keywords: Lamivudine; Interferon; Hepatitis B; Hepatitis B e antigen; Chronic hepatitis; Interferon nonresponder

Language: English

Document Type: Research article

DOI: 10.1016/S0168-8278(03)00076-X

Affiliations: 1: Division of Hepatology, University of Miami, Jackson Medical Towers, 1500 N.W. 12th Avenue, Suite 1101, 33136, Miami, FL, USA

This article is hosted on another website.

You may be required to register, activate a subscription or purchase the article before you can obtain the full text.

Proceed

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A